Harbin Pharmaceutical Group Co Ltd

Harbin Pharmaceutical Group released its 2026 interim report. Total operating revenue was 8.296 billion yuan, up 2.10% year on year, and net profit attributable to the parent company was 410 million yuan, up 57.99% year on year. Net cash flow from operating activities was negative 46.2668 million yuan, an increase of 94.9733 million yuan compared with the same period last year. The asset-liability ratio was 52.96%, down 1.75 percentage points from a year earlier. Gross margin was 26.38%, up 2.27 percentage points from the previous quarter. Return on equity was 6.72%, up 2.09 percentage points year on year. Diluted earnings per share were 0.16 yuan, up 58.00% year on year. Total asset turnover was 0.57 times, up 1.11% year on year. The number of shareholders was 109,800, and the top ten shareholders held 51.80% of total share capital.

Innovative drug concept stock Baihua Pharmaceutical achieved its 5th consecutive daily limit, Harbin Pharmaceutical Group hit its 2nd consecutive daily limit, and Bio-Techne surged over 18%. In related news, WuXi AppTec announced that a U.S. court has ruled on its preliminary injunction motion, shielding the company from immediate adverse effects of the 1260H designation during the judicial process challenging that designation. The company had previously filed a lawsuit over the U.S. Department of Defense's decision to place it on the 1260H list.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Harbin Pharmaceutical Group announced that its subsidiary, Harbin Pharmaceutical Group Bioengineering, has received a Chemical API Marketing Authorization Approval Notice for potassium sulfate from the National Medical Products Administration. Potassium sulfate is one of the active pharmaceutical ingredients in the oral concentrated solution of magnesium sulfate, sodium sulfate, and potassium sulfate, acting as an osmotic laxative. Currently, there are 26 domestic companies with an A registration status for potassium sulfate API. The company has invested approximately 631,500 yuan in research and development.

A-shares plunged over the past week. Harbin Pharmaceutical became the top-performing stock with a weekly gain of 58.16%, while Meixin Technology led the decline with a drop of 41.12%. Harbin Pharmaceutical disclosed on July 9 that its attributable net profit for the first half of 2026 is expected to increase by 46.40% to 68.36%, and that 118 of its product specifications have been included in the new edition of the National Essential Medicines List. The stock hit consecutive daily limit-up moves, but the limit was broken on July 17, closing up 7.89%. Meixin Technology saw profit-taking after its share price hit a record high, plunging over 41% for the week. Despite revenue growth in the first quarter, net profit fell 33.32% year-on-year. Coupled with a broad sell-off in tech stocks, the share price underwent a sharp correction. All ten stocks on this week's bear list posted weekly declines exceeding 39%, mostly due to concentrated capital outflows after prior highs.

China's A-share market underwent volatile adjustments today, with the Shanghai Composite Index falling 1.85 percent and losing the 3,900-point level. However, the traditional Chinese medicine sector surged against the market, with Pien Tze Huang and ZBD Pharma hitting their daily limit up in the afternoon. The pharmaceutical and biological industry saw a net inflow of over 5 billion yuan in main funds, and the TCM sector index rose more than 3 percent at one point during the session, marking seven consecutive positive daily candlesticks. Harbin Pharmaceutical Group locked in its fifth straight daily limit up, while Hainan Haiyao achieved its second consecutive daily limit up. Chip stocks, on the other hand, suffered a broad sell-off, with the semiconductor sector index plunging more than 5 percent. Companies such as JCET and Demingli hit limit down in batches. Global chip stocks also faced heavy selling, with South Korea's SK Hynix tumbling 11.53 percent and Japan's Kioxia plummeting 15.03 percent. On the news front, the State Council approved the 15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine, and the 2026 edition of the National Essential Medicines List added 48 new proprietary Chinese medicines.

In early trading on July 16, Harbin Pharmaceutical hit its fifth consecutive daily limit, making it the stock with the longest winning streak among those still on a streak that day. The innovative drug theme remained strong, with Wanbang Pharmaceutical and Puruis rising over 10 percent. The on-device AI concept heated up, as Green Precision sealed a 20 percent daily limit, and Daoming Optics and Furong Technology also hit their daily limits. On the news front, seven on-device generative AI services completed regulatory filings, and the 2026 World Artificial Intelligence Conference is set to take place in Shanghai. The brain engineering sector saw a sudden surge during the session, with Chuangxin Medical hitting its daily limit in a straight line, and Saili Medical and Aipeng Medical following higher. The world's first implantable brain-computer interface system, NEO, saw its first prescription issued in Shanghai after receiving market approval. Total market turnover exceeded 1.4 trillion yuan, shrinking by 236.7 billion yuan compared with the same period last session, with over 3,200 stocks advancing.

The semiconductor sector tumbled, with Demingli, a storage leader valued at over 100 billion yuan, hitting limit down. Demingli issued a forecast projecting net profit attributable to shareholders of the parent company at 5.7 billion to 6.5 billion yuan for the first half of 2026, while its first-quarter net profit was 3.346 billion yuan. Based on this, second-quarter net profit is estimated to have fallen 5.74% quarter-on-quarter to 2.965 billion yuan. Shares of Muxi, Huatian Technology, and Youyan Silicon fell more than 9%. Innovative drug stocks remained active, with Harbin Pharmaceutical hitting its fourth consecutive daily limit up and Dizal Pharmaceutical surging by the 20% daily limit. Data from the National Medical Products Administration showed that the total value of out-licensing deals for innovative drugs in the first half of the year reached approximately 110 billion US dollars, already accounting for 80% of the full-year total for 2025.

On July 15, Harbin Pharmaceutical hit its fourth consecutive daily limit-up, with the innovative drug theme remaining active. Harbin Pharmaceutical opened sharply higher, Dizal Pharmaceutical hit its second consecutive 20 percent daily limit-up, and several stocks including BrightGene Bio-Medical Technology, GemPharmatech, and ChemPartner surged by the daily limit. In terms of news, Harbin Pharmaceutical disclosed that 118 of its product specifications have been included in the National Essential Medicines List 2026 Edition, with six new varieties added. Dizal Pharmaceutical signed a licensing agreement with AstraZeneca, granting it exclusive global rights to sunvozertinib, and will receive an upfront payment of 600 million US dollars and up to 900 million US dollars in milestone payments. In addition, in the first half of this year, China's innovative drug out-licensing deals totaled 81, with a total transaction value of approximately 110 billion US dollars, reaching a record high.